Aurinia Pharmaceuticals Inc (AUPH)
5.03
-0.06
(-1.08%)
USD |
NASDAQ |
Apr 24, 16:00
5.03
0.00 (0.00%)
After-Hours: 20:00
Aurinia Pharmaceuticals Net Income (Quarterly): -26.88M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -26.88M |
| September 30, 2023 | -13.45M |
| June 30, 2023 | -11.49M |
| March 31, 2023 | -26.21M |
| December 31, 2022 | -26.05M |
| September 30, 2022 | -8.989M |
| June 30, 2022 | -35.52M |
| March 31, 2022 | -37.63M |
| December 31, 2021 | -33.32M |
| September 30, 2021 | -50.26M |
| June 30, 2021 | -47.01M |
| March 31, 2021 | -50.38M |
| December 31, 2020 | -8.074M |
| September 30, 2020 | -42.13M |
| June 30, 2020 | -26.54M |
| March 31, 2020 | -25.93M |
| December 31, 2019 | -41.02M |
| September 30, 2019 | -19.04M |
| June 30, 2019 | -15.90M |
| March 31, 2019 | -12.43M |
| December 31, 2018 | -3.552M |
| September 30, 2018 | -18.34M |
| June 30, 2018 | -15.71M |
| March 31, 2018 | -15.48M |
| December 31, 2017 | -3.332M |
| Date | Value |
|---|---|
| September 30, 2017 | -13.12M |
| June 30, 2017 | -2.399M |
| March 31, 2017 | -51.94M |
| December 31, 2016 | -8.333M |
| September 30, 2016 | -7.419M |
| June 30, 2016 | -3.276M |
| March 31, 2016 | -4.267M |
| December 31, 2015 | -4.063M |
| September 30, 2015 | -5.21M |
| June 30, 2015 | -0.733M |
| March 31, 2015 | -8.601M |
| December 31, 2014 | -8.105M |
| September 30, 2014 | 4.438M |
| June 30, 2014 | -11.03M |
| March 31, 2014 | -4.775M |
| December 31, 2013 | -1.698M |
| September 30, 2013 | 0.792M |
| June 30, 2013 | -0.97M |
| March 31, 2013 | -0.786M |
| December 31, 2012 | -5.166M |
| September 30, 2012 | -1.729M |
| June 30, 2012 | -2.304M |
| March 31, 2012 | -0.455M |
| December 31, 2011 | -6.332M |
| September 30, 2011 | 2.160M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-50.38M
Minimum
Mar 2021
-8.074M
Maximum
Dec 2020
-28.73M
Average
-26.54M
Median
Jun 2020
Net Income (Quarterly) Benchmarks
| Lexaria Bioscience Corp | -0.6495M |
| Acasti Pharma Inc | -2.391M |
| Edesa Biotech Inc | -1.678M |
| Xenon Pharmaceuticals Inc | -44.74M |
| ESSA Pharma Inc | -5.964M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 45.10M |
| Total Expenses (Quarterly) | 74.77M |
| EPS Diluted (Quarterly) | -0.18 |
| Enterprise Value | 384.89M |
| Gross Profit Margin (Quarterly) | 88.04% |
| Profit Margin (Quarterly) | -59.60% |
| Earnings Yield | -10.54% |
| Normalized Earnings Yield | -10.54 |